An observational study in Sleep Apnea, Insomnia and Sleep Deprivation, sponsored by Brigham and Women's Hospital. Enrolling by invitation at 1 site in United States. Open to participants aged 25 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-10-27.
Sponsored by Brigham and Women's Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Sleep Apnea Syndromes by Brigham and Women's Hospital — 3 open to participants now, 3 under way, none of them phase 3. Sleep Apnea Syndromes · Brigham and Women's Hospital.
Among the 22 studies in Sleep Apnea Syndromes by Brigham and Women's Hospital, this one is the only one that started in 2024, is one of 5 observational ones, and was the 19th registered.
1,085 studies on the registry are indexed under Sleep Apnea Syndromes; 172 are open to participants now.
Browse Sleep Apnea Syndromes studies →3 of the 22 studies in Sleep Apnea Syndromes by Brigham and Women's Hospital are open now, in 1 country. Recruiting first, the newest first:
Brigham and Women's Hospital · Sites in United States
Ages 18+
Brigham and Women's Hospital · Sites in United States
Ages 18–79
By country, each count listing its studies:
Of the 119 Sleep Apnea Syndromes studies recruiting now, 58 (49%) set no upper age limit and 37 (31%) stop at 75 or younger; 25 take children under 18; 28 take healthy volunteers.
This study: 25 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5
First in 1990; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,680 is above the median of 150 across 343 observational studies indexed under Sleep Apnea Syndromes.
Median enrollment 47 across the 17 interventional studies, 300 across the 5 observational. Of the 16 that completed or were terminated, 5 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
Brigham and Women's Hospital is the lead sponsor of 1,270 studies on the registry; 230 are open to participants now.
Of its 117 completed or terminated interventional studies of FDA-regulated products, 65 (56%) have results posted.
1 of the studies in Sleep Apnea Syndromes by Brigham and Women's Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06336525Brigham and Women's HospitalAdult Sleep Health in the Rural Appalachia and Mississippi Delta Region and Its Relationships With Cardiometabolic Health Disparities. | 2027-01-31 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Sleep Apnea Syndromes by Brigham and Women's Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Rural communities in the southern U.S. suffer a disproportionate burden of morbidity and mortality from cardiometabolic disease, with traditional risk factors explaining only a modest proportion of the excess burden of disease. There is considerable evidence that multiple dimensions of sleep health, including sleep duration, efficiency, timing, and regularity, as well as the disorders sleep apnea and insomnia, affect cardiometabolic disease risk. However, there is currently a lack of systematically developed sleep data in rural populations. The RURAL Sleep Study is an ancillary study to a recently initiated longitudinal epidemiology study in rural Appalachia and Mississippi Delta (the RURAL Study). The RURAL Sleep Study will add measures of sleep health to the complex individual, social and environmental factors and health outcome measures being evaluated by the RURAL Study, by incorporating minimally burdensome measures of multiple dimensions of sleep health. The results are expected to inform health care providers, public health officials, and the general public of the prevalence, risk factors, and consequences of impaired sleep health in these rural communities, providing a critical basis for prevention, recognition, and management of sleep disorders and improvement of sleep and cardiometabolic health.
Rural communities in the southern U.S. suffer a disproportionate burden of morbidity and mortality from cardiometabolic disease, with traditional risk factors explaining only a modest proportion of the excess burden of disease. Growing evidence implicates poor sleep health as an important risk factor for cardiometabolic disease. While this is most well established for sleep apnea and insomnia, there is considerable evidence that multiple dimensions of sleep health, including sleep duration, efficiency, timing, and regularity, also affect cardiometabolic disease risk. Moreover, rural Southern communities are likely to experience high rates of impaired sleep health, reflecting high levels of psychosocial and environmental stressors, such as financial stress, social isolation, environmental pollution, and poor built environment in addition to high rates of smoking and obesity. However, there is currently a lack of systematically developed sleep data in rural populations.
Recognizing the paucity of research on cardiometabolic risk in this high-risk rural population, the NHLBI recently initiated a new longitudinal epidemiology study in rural Appalachia and Mississippi Delta (the RURAL Study) to identify the complex individual, social and environmental factors contributing to this high burden of disease. The proposed RURAL Sleep Study will complement the RURAL Study by incorporating minimally burdensome measures of multiple dimensions of sleep health at the time of baseline cohort assessment in approximately 4000 adults age 25-64 years, utilizing mobile health technologies to
These data will allow us to leverage the planned extensive assessments of cardiometabolic risk factors, subclinical disease, and psychosocial and environmental stressors (and resilience factors) to address the following specific aims:
Aim 1a. Quantify population distributions of sleep health measures in a rural cohort along dimensions of sleep apnea, insomnia, chronotype, and sleep duration, efficiency, timing, and regularity.
Aim 1b. Identify psychosocial, behavioral, and environmental correlates of sleep health in rural communities.
Aim 2. Assess the association of sleep health with cardiometabolic risk factors and subclinical cardiovascular disease independent of other established cardiovascular and metabolic risk factors.
The results are expected to inform health care providers, public health officials, and the general public of the prevalence, risk factors, and consequences of impaired sleep health in these rural communities, providing a critical basis for prevention, recognition, and management of sleep disorders and improvement of sleep and cardiometabolic health.
The cohort will consist of a general population sample of adults age 25-64 years residing in 10 counties in the rural Appalachia and Mississippi Delta regions (AMD): Alabama, Mississippi, Louisiana, and Kentucky, with counties sampled proportional to their populations. The projected RURAL Study sample size is 4600 individuals, with approximately equal numbers in each of the four age deciles. The sample is anticipated to include 51.7% women and 48.3% men. The projected racial/ethnic make-up of the sample is 63.8% non-Hispanic white, 32.7% non-Hispanic black, 1.7% Hispanic and 1.8% other.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Oxygen desaturation index
Frequency of 4% drops in nocturnal blood oxygen saturation
Time frame: 7 nights
Insomnia Severity Index
min: 0, max: 28, higher score indicates more insomnia symptoms
Time frame: Single measurement at baseline
Sleep Duration
Mean total sleep time from accelerometry
Time frame: 3-6 months
Sleep Duration Regularity
Variability in total sleep time from accelerometry
Time frame: 3-6 months
Sleep Timing
Sleep midpoint from accelerometry
Time frame: 3-6 months
Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep-related Impairment Short Form 8a
raw score min: 8, max: 40; higher score indicates greater impairment
Time frame: Single measurement at baseline
Restless Legs Syndrome (RLS)
Restless Legs Syndrome, yes/no
Time frame: Single measurement at baseline
Chronotype
Body's natural tendency to go to sleep and wake up at certain times
Time frame: Single measurement at baseline
Sleep Timing Regularity
Variability in sleep midpoint from accelerometry
Time frame: 7 days
Global Sleep Quality
Pittsburgh Sleep Quality Index (PSQI), min: 0, Max: 21; higher score indicates poorer sleep quality Minimum Score = 0 (better); Maximum Score = 21 (worse) Interpretation: TOTAL \< 5 associated with good sleep quality TOTAL \> 5 associated with poor sleep quality
Time frame: Single measurement at baseline
Oxygen desaturation index, 3%
Frequency of 3% drops in nocturnal blood oxygen saturation
Time frame: 7 days
Plan to share: Yes — De-identified oximetry data and the results of sleep questionnaires will be shared via the National Sleep Research Resource (NSRR) (sleepdata.org). The RURAL sleep data will be available for any researcher who provides an acceptable Data Access and Use Agreement and has appropriate regulatory approvals. The NSRR has procedures to streamline Institutional Review Board (IRB) approval (via an in house IRB process). The NSRR is in the process of migrating to Bio Data Catalyst, enabling easy linkage and interoperability with other Bio Data Catalyst data (from RURAL) and other cohorts to individuals with approved Database of Genotypes and Phenotypes (dbGaP) authorization. Other RURAL Study data that are integral to this project but were collected separately by the parent RURAL Study (e.g., non-sleep cardiovascular risk and outcomes data) will be distributed via RURAL Study data sharing mechanisms, including via Bio Data Catalyst and dbGaP.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Within one year of publication of primary study results.
No publications or documents are linked to this record.
Started May 2024 (actual). Primary completion is estimated for Jan 2027, 32 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Brigham and Women's Hospital →